AVTX Stock Summary and Trading Ideas (Avalo Therapeutics | NASDAQ:AVTX)

Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.

Avalo Therapeutics trades on the NASDAQ stock market under the symbol AVTX.

As of September 28, 2026, AVTX stock price declined to $15.08 with 710,828 million shares trading.

AVTX has a beta of 1.48, meaning it tends to be more sensitive to market movements. AVTX has a correlation of 0.04 to the broad based SPY ETF.

AVTX has a market cap of $808.74 million. This is considered a Small Cap stock.

In the last 3 years, AVTX traded as high as $52.75 and as low as $3.39.

The top ETF exchange traded funds that AVTX belongs to (by Net Assets): VTI, XBI, IWM, VXF, VTWO.

AVTX has outperformed the market in the last year with a return of +30.6%, while the SPY ETF gained +17.5%. However, in the most recent history, AVTX shares have underperformed the stock market with its stock returning -16.2% in the last 3 month period and -6.5% for the last 2 week period, while SPY has returned +4.5% and +0.4%, respectively.

AVTX support price is $14.78 and resistance is $16.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVTX shares will trade within this expected range on the day.